KR20050071514A - Cb2 수용체 조절제로서의 피리딘 유도체 - Google Patents

Cb2 수용체 조절제로서의 피리딘 유도체 Download PDF

Info

Publication number
KR20050071514A
KR20050071514A KR1020057005234A KR20057005234A KR20050071514A KR 20050071514 A KR20050071514 A KR 20050071514A KR 1020057005234 A KR1020057005234 A KR 1020057005234A KR 20057005234 A KR20057005234 A KR 20057005234A KR 20050071514 A KR20050071514 A KR 20050071514A
Authority
KR
South Korea
Prior art keywords
alkyl
chloro
formula
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057005234A
Other languages
English (en)
Korean (ko)
Inventor
리차드 하워드 그린
앤드류 존 이더톤
제라드 마틴 폴 기블린
카람지트 싱 잔두
윌리엄 레오나르드 미첼
알란 네일러
지오반니 팔롬비
데렉 안토니 라울링스
브라이언 피터 슬링스비
앤드류 리차드 위팅톤
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20050071514A publication Critical patent/KR20050071514A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057005234A 2002-09-27 2003-09-25 Cb2 수용체 조절제로서의 피리딘 유도체 Withdrawn KR20050071514A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0222493.9 2002-09-27
GBGB0222493.9A GB0222493D0 (en) 2002-09-27 2002-09-27 Compounds

Publications (1)

Publication Number Publication Date
KR20050071514A true KR20050071514A (ko) 2005-07-07

Family

ID=9944904

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057005234A Withdrawn KR20050071514A (ko) 2002-09-27 2003-09-25 Cb2 수용체 조절제로서의 피리딘 유도체

Country Status (23)

Country Link
US (1) US20060240048A1 (cg-RX-API-DMAC7.html)
EP (1) EP1565442B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006503845A (cg-RX-API-DMAC7.html)
KR (1) KR20050071514A (cg-RX-API-DMAC7.html)
CN (1) CN1703402A (cg-RX-API-DMAC7.html)
AR (1) AR041395A1 (cg-RX-API-DMAC7.html)
AT (1) ATE378317T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003268907A1 (cg-RX-API-DMAC7.html)
BR (1) BR0314635A (cg-RX-API-DMAC7.html)
CA (1) CA2500231A1 (cg-RX-API-DMAC7.html)
DE (1) DE60317555T2 (cg-RX-API-DMAC7.html)
ES (1) ES2294313T3 (cg-RX-API-DMAC7.html)
GB (1) GB0222493D0 (cg-RX-API-DMAC7.html)
IS (1) IS7809A (cg-RX-API-DMAC7.html)
MA (1) MA27448A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05003263A (cg-RX-API-DMAC7.html)
NO (1) NO20052028L (cg-RX-API-DMAC7.html)
NZ (1) NZ538943A (cg-RX-API-DMAC7.html)
PL (1) PL375990A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005112752A (cg-RX-API-DMAC7.html)
TW (1) TW200413321A (cg-RX-API-DMAC7.html)
WO (1) WO2004029026A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502084B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
SE0401343D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
BRPI0614272A2 (pt) * 2005-08-09 2011-03-22 Glaxo Group Ltd derivados de imidazopiridinas como ligantes de receptores canabinóides
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
JP2009536613A (ja) * 2006-04-07 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節する化合物
WO2008040649A2 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2008063625A2 (en) * 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
BRPI0721268A2 (pt) * 2007-02-22 2013-01-15 Hemerus Medical Llc dispositivo de filtragem de fluido biol[ogico, mÉtodo para processar um fluido biolàgico, sistema de filtragem de fluido biolàgico
WO2010084767A1 (en) * 2009-01-22 2010-07-29 Raqualia Pharma Inc. N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity
CA2757188A1 (en) 2009-03-30 2010-10-07 Astellas Pharma Inc. Pyrimidine compound
SG178867A1 (en) * 2009-08-24 2012-04-27 Neuralstem Inc Synthesis of a neurostimulative piperazine
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013048962A (ja) * 2012-12-12 2013-03-14 Hemerus Medical Llc 大容量の体液濾過装置
WO2018055640A1 (en) * 2016-09-22 2018-03-29 Srf Limited Process for the preparation of haloalkyl derivatives of nicotinic acid
MX2020012760A (es) 2018-06-27 2021-03-25 Hoffmann La Roche Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
EP3814328B1 (en) 2018-06-27 2026-03-11 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine compounds as inhibitors of cannabinoid receptor 2
WO2020025574A1 (en) 2018-08-03 2020-02-06 Bayer Aktiengesellschaft Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process
EP3666759A1 (en) 2018-12-10 2020-06-17 Bayer Aktiengesellschaft Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands

Also Published As

Publication number Publication date
NZ538943A (en) 2007-01-26
EP1565442B1 (en) 2007-11-14
WO2004029026A1 (en) 2004-04-08
PL375990A1 (en) 2005-12-12
ATE378317T1 (de) 2007-11-15
TW200413321A (en) 2004-08-01
JP2006503845A (ja) 2006-02-02
ES2294313T3 (es) 2008-04-01
AR041395A1 (es) 2005-05-18
DE60317555T2 (de) 2008-10-23
RU2005112752A (ru) 2006-01-20
CA2500231A1 (en) 2004-04-08
CN1703402A (zh) 2005-11-30
US20060240048A1 (en) 2006-10-26
MXPA05003263A (es) 2005-07-05
GB0222493D0 (en) 2002-11-06
DE60317555D1 (de) 2007-12-27
ZA200502084B (en) 2006-02-22
NO20052028L (no) 2005-06-03
BR0314635A (pt) 2005-08-02
AU2003268907A1 (en) 2004-04-19
EP1565442A1 (en) 2005-08-24
MA27448A1 (fr) 2005-07-01
IS7809A (is) 2005-04-19

Similar Documents

Publication Publication Date Title
EP1562907B1 (en) Pyridine derivatives as cb2 receptor modulators
EP1565442B1 (en) Pyridine derivatives as cb2 receptor modulators
EP1539712B1 (en) Pyrimidine derivatives and their use as cb2 modulators
US20070219229A1 (en) Pyrrolopyridine Derivatives
EP1534687B1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators
US20080280952A1 (en) Pyridine Derivatives as Connabinoid Receptor Modulators
EP1718613B1 (en) Pyridine derivatives and their use as cb2 receptor modulators
US20090018128A1 (en) Compounds
JP2007520538A (ja) 医薬において用いるためのcb2モジュレーターおよびpde4阻害剤の組合せ
WO2005080350A1 (en) Pyrimidine derivatives as cannabinoid receptor modulators
US20090264452A1 (en) 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders
KR20080034457A (ko) 카나비노이드 수용체 리간드로서의 이미다조피리딘 유도체
HK1079193B (en) Pyrimidine derivatives and their use as cb2 modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050325

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid